ESC 365 - Cost-effectiveness of apixaban vs aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial

ESC2025 Premium Access

Cost-effectiveness of apixaban vs aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial

Session: Public health and health economics

Topic: Health Economics

Speaker: Doctor R. Sandhu (Calgary, CA)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Roopinder Sandhu

University of Calgary, Calgary (Canada)

1 follower

6 more presentations in this session

Global burden of cardiovascular disease and its attributable risk factors and trends in european union countries from 1990 to 2021: a benchmarking analysis for the global burden of disease study 2021

Speaker: Ms A. Parisapogu (Farmington, US)

Cardiovascular risk factor prevalence, treatment, and control among US adults by income, 2009-2023.

Speaker: Doctor L. Marinacci (Boston, US)

Comparative validation of the AHA PREVENT equation with US and European cardiovascular risk equations among 892,000 adults

Speaker: Doctor J. Diao (Boston, US)

Should body mass index categories differ by ethnicity? All-cause mortality and incident cardiovascular disease in a multi-ethnic cohort of 400,000 adults

Speaker: Mr C. Li (Auckland, NZ)

Impact of abnormal findings in health check-ups on medical care: findings from 15 years of health check-ups

Speaker: Doctor S. Kameda (Shimotsuke, JP)

Access the full session

Public health and health economics

Speakers: Doctor R. Sandhu, Ms A. Parisapogu, Doctor L. Marinacci, Doctor J. Diao, Mr C. Li...

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources